Tempest Weighs M&A, Analyst Sees A Broken Story Despite Phase 2 Liver Cancer Study Success
AZNTempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings
AZNThe EU approved AstraZeneca's Enhertu for certain breast cancer patients and Imfinzi for resectable NSCLC, showing significant survival benefits.
The European Commission Approves AstraZeneca And Daiichi Sankyo's Enhertu (Trastuzumab Deruxtecan) As Monotherapy For Adult Patients With Unresectable Or Metastatic Hormone Receptor-positive, HER2-low Or HER2-ultralow Breast Cancer Who Have Received At Le
AZNThe European Commission Approves AstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy For Adults With Resectable Non-small Cell Lung Cancer At High Risk Of Recurrence And No Epidermal Growth Factor Receptor Mutations Or Anaplastic Lymphoma
AZNPeering Into AstraZeneca's Recent Short Interest
AZNFDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
AZNFDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.
AstraZeneca Announces FDA Approves Adjuvant Durvalumab/Chemo In Muscle-Invasive Bladder Cancer
AZNPresident Trump Says Will Be Announcing Pharma Tariffs Soon
AZNJapan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
AZNBridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it.
J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study
AZNJohnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line EGFR-mutated NSCLC over osimertinib.
Reported Earlier, AstraZeneca's TAGRISSO Data from LAURA, SAVANNAH, And ORCHARD Trials Highlight Continued Survival Gains And Expanded Role in EGFR+ Lung Cancer
AZNSyneron Bio Announces Strategic Collaboration With AstraZeneca To Develop Potential First-In-Class Macrocyclic Peptides For The Treatment Of Chronic Diseases; AstraZeneca Will Provide Upfront Payments And Potential Near-Term Milestone Payments Totaling $7
AZNAstraZeneca Announced Global Collaboration With Harbour BioMed To Develop Next-Gen Therapeutic Antibodies, Including $105M Equity Investment, $175M Upfront, Up To $4.4B In Milestones, And Acquisition Of 9.15% Newly Issued Shares Of Harbour BioMed
AZNAstraZeneca Announced $2.5B Investment In Beijing To Establish Sixth Global R&D Centre, Sign Major Research And Manufacturing Agreements To Advance Life Sciences In China
AZNA Potential Challenger For AstraZeneca's Blockbuster Lung Cancer Drug?
AZNAstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug.
Eventful Monday For AstraZeneca - What's Going On?
AZNAstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for small cell lung cancer treatment.
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details
AZNAstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion deal includes an initial payment of $425 million, with additional contingent consideration.
The European Union Has Approved AstraZeneca's Imfinzi (Durvalumab) As Monotherapy For Limited-stage Small Cell Lung Cancer Whose Disease Has Not Progressed Following Platinum-based Chemoradiation Therapy
AZNAstraZeneca Released High-level Results From CALYPSO Phase 3 Trial Showing That Eneboparatide (AZP-3601) Met Its Primary Endpoint With Statistical Significance In Adults With Chronic Hypoparathyroidism At 24 Weeks, Compared To Placebo
AZNAstraZeneca And Alteogen Have Entered Into An Exclusive License Agreement, AstraZeneca Will Acquire Worldwide Rights To Use ALT-B4 To Develop And Commercialize Subcutaneous Formulations Of Several Oncology Assets
AZNAstraZeneca To Acquire EsoBiotec For Up To $1B, Advancing In Vivo Cell Therapy Capabilities With Breakthrough ENaBL Platform
AZNPerspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
AZNH.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
AZNVivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
AZNIonis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.
Ionis and AstraZeneca Win EU Approval for WAINZUA, a Self-Injectable Treatment for Rare Nerve Disease
AZN'U.S. CDC Plans Large Study Into Potential Connections Between Vaccines And Autism, Sources Say' - Reuters News
AZNAstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients
AZNAstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong trend in overall survival.
AstraZeneca Says IMFINZI (durvalumab)-based Regimen Demonstrated Improvement In Event-free Survival In Resectable Early-stage Gastric And Gastroesophageal Junction Cancers
AZNKiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
AZNKiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis.
Enhertu Releases Results In Overall Survival For HER2 Positive Metastatic Gastric Cancer In Destiny-Gastric04 Phase 3 Trial Interim Analysis
AZNAstraZeneca's Imfinzi (Durvalumab) In Combination With Chemotherapy Has Been Recommended For Approval In The European Union For Adult Patients With Resectable Non-small Cell Lung Cancer
AZNIonQ CEO Fires Back At Nvidia's Jensen Huang: 'We Remain The 800 Pound Guerrilla'
AZNIonQ CEO Niccolo De Masi is confident that quantum computing will soon be the third leg of computing. With major partnerships and predicted GAAP revenue, IonQ is poised to be a leader in the industry.
Snowflake Expands Microsoft, OpenAI Partnership: Will Include Other Prominent Models Like Anthropic's Claude, Meta's Llama, And DeepSeek
AZNSnowflake unveiled its deeper partnership with Microsoft Corp during its earnings call and introduced its new AI agent Cortex.
AstraZeneca's SERENA-6 Study Assesses Camizestrant for HR-Positive Breast Cancer, Key Outcomes Awaited
AZN'New Coronavirus With Pandemic Potential Discovered In China' - DailyMail
AZNAmid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
AZNFibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent.
FibroGen Announced The Sale Of Its China Subsidiary To AstraZeneca For Approximately $160M
AZNBig Money Is Betting On Europe, Should You? 3 ETFs To Watch
AZNEuropean fund managers are bullish on stocks, with 3 top ETFs to consider: SPDR EURO STOXX 50 (FEZ), Vanguard FTSE Europe (VGK), Xtrackers MSCI EAFE Hedged Equity (DBEF)
George Soros Makes Fresh Bets On Alphabet, Small Caps: What About SPY Puts And Alibaba?
AZNSoros Fund Management made bullish bets on Alphabet and small-cap stocks while reducing exposure to SPY and Chinese tech in Q4.
'AstraZeneca Hit With US Class Action Lawsuit Over China Regulatory Probes; Lawsuit Claims UK Pharma Giant Understated The Risk Of Government Investigations' - Financial Times
AZN10 Health Care Stocks Whale Activity In Today's Session
AZNHow Is The Market Feeling About AstraZeneca?
AZNSoros Fund Management Raises Share Stake In AstraZeneca By 19% To 3.2M Sponsored ADRs
AZNTrump Order Halts Funding For School Covid Vaccine Mandates
AZNAstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients
AZNAstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority Review expected in Q2 2025.
AstraZeneca's IMFINZI Perioperative Regimen Improved Event-Free Survival And Overall Survival Across Muscle-Invasive Bladder Cancer Patients Regardless Of Complete Pathology Response Status In Post-Hoc Exploratory Analysis Of Niagara Phase III Trial
AZNThis AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
AZNUBS Upgrades AstraZeneca to Buy
AZNTrade Desk, Leidos, Devon Energy And A Major Health Care Stock On CNBC's 'Final Trades'
AZNFDA Grants Priority Review to Daiichi Sankyo and AstraZeneca's Datopotamab Deruxtecan for Advanced Lung Cancer Treatment
AZN